Omada Health has revealed promising results from a study that looked at how well its digital health tools could help spur weight loss among Medicare members, a milestone for the company a couple of months after it roped in new funding to develop its health management program.
Myriad Genetics has inked a three-year contract with Tufts Health Plan to provide its Prolaris biopsy test for members diagnosed with localized prostate cancer.
Should Medicare be allowed to square off with pharma on drug prices? Presidential candidate Hillary Clinton was the latest politician to propose it, joining Democratic rival Sen. Bernie Sanders, President Obama--and a variety of other lawmakers before them.
Cancer drug spending has drawn the ire of payers, patients and doctors unhappy with skyrocketing costs for the meds. Now another voice is joining the chorus of naysayers, as a new report from a cancer community nonprofit organization found that a government discount drug program is profiting off the rising costs of cancer meds.
Myriad Genetics nabbed Medicare coverage for its prostate cancer screening test, a win for the company as it struggles with waning revenues and increased competition from rivals in the genetic testing market.
President Obama has support for his idea that Medicare needs the power to negotiate drugs prices. The vast majority of consumers think it is a good idea as well.
Theranos has major ambitions--and, if you glance at the composition of its board, it's obvious that diagnostics cost-savings on the massive scale of the U.S. government is at the core of them. Now, it's made a first partnership that moves it toward realizing that goal. It will offer diagnostic testing through managed care provider AmeriHealth Caritas, which serves more than 6.6 million patients across 16 states and the District of Columbia--the bulk of whom are on Medicaid.
U.S. payers are striking out at drug spending again, highlighting the cost to taxpayers. According to a commissioned report, 10 hot new "breakthrough" meds are expected to cost publicly funded healthcare plans more than $50 billion over the next decade.
Pharma companies that make payments to doctors--and the doctors who receive those payments--have repeatedly insisted there's no link between those payments and prescriptions. But data on Medicare's top script writers may have them answering for it all over again.
Pharma companies that make payments to doctors--and the doctors who receive them--repeatedly insist there's no link between those payments and prescribing habits. But data on Medicare's top script writers show the highest prescribers of particular meds collect big payments from the makers of those very drugs.